Nadezda Masloboeva

Nadezda Masloboeva has extensive work experience in the biotechnology and pharmaceutical industries. Nadezda is currently working as the Director of Biomarker Strategy at Sarepta Therapeutics. Prior to this, they held positions at Finch Therapeutics and Rubius Therapeutics, where they played key roles in translational medicine and biomarker development. Nadezda also worked as a Scientific Consultant at Genedata, leading genomic and biomarker analysis projects. Nadezda has a strong academic background, including a postdoctoral fellowship at Harvard University and a graduate student and teaching assistant role at ETH Zurich. Nadezda has also worked as a research associate at the Vavilov Institute of General Genetics and as a technician at the DNA Sequencing Center of the Russian Academy of Sciences. Nadezda's expertise spans various scientific disciplines, including bioinformatics, molecular biology, and microbiology. Their contributions to research and industry have helped advance understanding and application of biomarkers and therapeutic strategies.

Nadezda Masloboeva completed their education at Novosibirsk State University (NSU) from 2002 to 2007, where they obtained a Master of Science (MS) in Molecular Biology. Nadezda then pursued a Doctor of Philosophy (PhD) in Microbiology, General at ETH Zürich from 2009 to 2013. Additionally, they have obtained certifications in various subjects including Corporate Finance, Microeconomics Principles, and Statistics in Medicine from institutions such as Coursera and Stanford University in 2013.